StockData

Cellyan Biotechnology vs DataMeds AI

HKPD and MEDS side by side, both in wholesale trade-non-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HKPD and MEDS compare

Cellyan Biotechnology grew revenue faster over the last twelve months (−33.9% versus −77.5% for DataMeds AI).

Cellyan Biotechnology keeps more of each dollar of sales as profit, with a net margin of −8.5% compared with −565% at DataMeds AI.

Cellyan Biotechnology scores higher on the StockData Score (3 against 1 for DataMeds AI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHKPDMEDS
Size and price
Market cap–$2.0M
Share price$1.52$0.640
Change, 1 year−93.5%−98.0%
Beta (5Y)–0.34
Employees235
StockData Score
Total score3 (better)1
Valuation score01 (better)
Growth score00
Performance score1 (better)0
Health score2 (better)0
Dividend score00
Valuation
P/S–0.3×
Growth
Revenue growth (TTM)−33.9% (better)−77.5%
Profitability
Gross margin10.3% (better)−92.1%
Operating margin−17.8% (better)−548%
Net margin−8.5% (better)−565%
FCF margin−5.9%–
Return on equity−15.5% (better)−1707%
Return on invested capital−22.5% (better)−153%
Financial health
Debt / equity0.09–
Interest coverage−17.8×−6.2× (better)
Current ratio3.86 (better)0.14
Altman Z-score–−8.90
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions1.5%1.7%
Held by insiders81.9%–
Short interest, % of float0.57%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.